Towards 2000—New Strategies for Acute Coronary Syndromes (II) Paul Wayne Armstrong Legacy Pages: S85 - S87
Plaque Disruption: Pathogenesis and Prevention James S. ForresterPrediman K. Shah OriginalPaper Pages: S89 - S97
Coronary Artery Disease: The View from Intravascular Ultrasound Steven E. NissenE. Murat Tuzcu OriginalPaper Pages: S99 - S111
The Role of Enzymatic Markers in the New Millennium: Point-of-Care Testing and Beyond L. Kristin NewbyRobert H. ChristensonE. Magnus Ohman OriginalPaper Pages: S113 - S118
St Segment Monitoring in Patients with Acute Ischemic Syndromes: Past and Future Anatoly LangerP.W. Armstrong OriginalPaper Pages: S119 - S123
Thrombolytic or Angioplasty Therapy of Evolving Myocardial Infarction? Eric J. Topol OriginalPaper Pages: S125 - S131
New Thrombolytics: A Light at the End of the Tunnel? Frans Van de Werf OriginalPaper Pages: S133 - S135
Antiplatelet Therapy in Coronary Disease: What Agent to Use, When, and How? Pierre Theroux OriginalPaper Pages: S143 - S150
New Agents, New Trials, New Solutions Robert M. CaliffRobert A. Harrington OriginalPaper Pages: S151 - S159
Health Economics of Acute Coronary Syndromes Daniel B. MarkEric D. Peterson OriginalPaper Pages: S161 - S168
Use and Impact of Registries for Myocardial Infarction on Process of Care and Outcomes: Examples from Canada Jafna L. Cox OriginalPaper Pages: S169 - S175